Myosin in autoinhibited
Journal
bioRxiv : the preprint server for biology
Titre abrégé: bioRxiv
Pays: United States
ID NLM: 101680187
Informations de publication
Date de publication:
28 Aug 2023
28 Aug 2023
Historique:
pubmed:
24
4
2023
medline:
24
4
2023
entrez:
24
04
2023
Statut:
epublish
Résumé
Mavacamten is a novel, FDA-approved, small molecule therapeutic designed to regulate cardiac function by selectively but reversibly inhibiting the enzymatic activity of myosin. It shifts myosin towards ordered
Identifiants
pubmed: 37090664
doi: 10.1101/2023.04.10.536292
pmc: PMC10120679
pii:
doi:
Types de publication
Preprint
Langues
eng
Déclaration de conflit d'intérêts
Competing interests C.Z and R.S are employees and own shares in Bristol Myers Squibb (formerly MyoKardia Inc.). S.N and S.G are former employees of Bristol Myers Squibb. C.dR. has a consulting relationship with Bristol Myers Squibb. S.M.M and M.P are partners in FilamenTech, Inc. and they provided the simulations at no cost. W.M and T.C.I consult for Edgewise Therapeutics Inc., but this activity has no relation to the current work.